公开(公告)号：US5629021A

公开(公告)日：1997-05-13

申请号：US380942

申请日：1995-01-31

Applicant: D. Craig Wright

Inventor： D. Craig Wright

IPC: A61K9/107 ,  A61K31/565 ,  B01J13/00 ,  A61K9/14

CPC classification number: A61K9/1075 ,  Y10S977/773 ,  Y10S977/915 ,  Y10S977/926

Abstract: The present invention relates to micellar nanoparticles and methods of their production. Micellar nanoparticles are made by hydrating a mixture of an oil, a stabilizer/surfactant, and an alcoholic initiator with an aqueous solution. These micellar nanoparticles are normally less than 100 nanometers in diameter. The micellar nanoparticles are particularly advantageous in delivering materials such as estradiol topically through the skin because their small size allows easy penetration.

Abstract translation: 本发明涉及胶束纳米粒子及其制备方法。 通过用水溶液将油，稳定剂/表面活性剂和醇引发剂的混合物水合来制备胶束纳米颗粒。 这些胶束纳米粒子通常直径小于100纳米。 胶束纳米粒子特别有利于通过皮肤递送材料如雌二醇，因为它们的小尺寸允许容易的渗透。

公开(公告)号：US20100143393A1

公开(公告)日：2010-06-10

申请号：US12300427

申请日：2007-05-11

Applicant: Gale Smith ,  Rick Bright ,  D. Craig Wright

Inventor： Gale Smith ,  Rick Bright ,  D. Craig Wright

IPC: A61K39/145 ,  C07K14/00 ,  A61P31/16

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55555 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention includes novel influenza antigenic formulations and vaccines that comprise influenza M2 peptide and VLPs comprising influenza M2 protein. The invention also includes methods of making and administering the novel antigenic formulation and vaccine. The invention also include methods of inducing immunity to ameliorate and/or prevent influenza infections in a subject.

Abstract translation: 本发明包括新型流感抗原制剂和包含流感M2肽和包含流感M2蛋白的VLP的疫苗。 本发明还包括制备和施用新型抗原制剂和疫苗的方法。 本发明还包括诱导免疫力改善和/或预防受试者流感感染的方法。

公开(公告)号：US07393541B2

公开(公告)日：2008-07-01

申请号：US10846939

申请日：2004-05-13

Applicant: D. Craig Wright ,  Joan Brisker ,  Mark A. Chambers

Inventor： D. Craig Wright ,  Joan Brisker ,  Mark A. Chambers

IPC: A61K39/00 ,  A61K39/04 ,  A61K39/38 ,  A61K45/00 ,  A01N65/00 ,  A01N63/00 ,  A01N1/00

CPC classification number: A61K39/04 ,  A61K2039/521 ,  A61K2039/55555

Abstract: Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome® adjuvant, as well as methods for using such compositions.

Abstract translation: 公开了用于增强受试者的免疫力或接种受试者免受分枝杆菌感染的组合物和方法。 本发明提供了包含分枝杆菌如牛分枝杆菌的福尔马林灭活的培养物和Novasome佐剂的组合物，以及使用这些组合物的方法。

公开(公告)号：US5866140A

公开(公告)日：1999-02-02

申请号：US361821

申请日：1994-12-22

Applicant: Ali Ibrahim Fattom ,  Walter W. Karakawa, deceased ,  D. Craig Wright

Inventor： Ali Ibrahim Fattom ,  Walter W. Karakawa, deceased ,  D. Craig Wright

IPC: A61K39/395 ,  A61K39/00 ,  A61K39/002 ,  A61K39/085 ,  A61K39/09 ,  A61P31/04 ,  A61P37/04 ,  C07K14/195 ,  C07K14/41 ,  C07K14/705 ,  C07K16/00 ,  C07K16/12 ,  C12P19/04 ,  C12Q1/14 ,  G01N33/569 ,  A61K39/02 ,  A61K45/00

CPC classification number: A61K39/085 ,  C07K16/1271 ,  C12P19/04 ,  A61K39/00

Abstract: A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.

公开(公告)号：US5795582A

公开(公告)日：1998-08-18

申请号：US597938

申请日：1996-02-07

Applicant: D. Craig Wright

Inventor： D. Craig Wright

IPC: A61K39/145 ,  A61K39/39 ,  A61K9/00 ,  A61K47/48

CPC classification number: A61K39/39 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K2039/5252 ,  A61K2039/645 ,  A61K2039/70 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y10S424/16

Abstract: A new method of adjuvanting a variety of materials has been developed. Starburst dendrimers, primarily poly(amidoamine) starburst dendrimers, can be used as an adjuvant for Influenza antigen and similar materials. Mid-Generation dendrimers are preferred and yield high antibody titer levels with reduced antigen dosage.

Abstract translation: 已经开发了一种佐剂各种材料的新方法。 Starburst树枝状大分子，主要是聚（酰胺胺）星爆树枝状大分子，可用作流感抗原和类似材料的佐剂。 中一代树枝状大分子是优选的，并且产生抗体滴度高的抗体，抗原剂量降低。

公开(公告)号：US5662957A

公开(公告)日：1997-09-02

申请号：US643171

申请日：1996-05-03

Applicant: D. Craig Wright

Inventor： D. Craig Wright

IPC: A23D7/005 ,  A23D7/04 ,  A23K1/00 ,  A23K1/18 ,  A61K9/127

CPC classification number: A23D7/0053 ,  A23D7/04 ,  A23K40/30 ,  A23K50/80 ,  A61K9/1272 ,  Y10S514/938

Abstract: Disclosed is a new class of lipid vesicles, liposoils, which have high oil content, low water content, and protein. The liposoils are made using a combination of a surfactant and either dried egg yolk or dried whole egg as the wall material, oil, and an aqueous diluent. Unlike most lipid vesicles, the liposoils can be made with an aqueous diluent having high salinity; in fact, sea water is a preferred aqueous diluent. Liposoils have particular applicability as a food for marine environments, such as a food source for filter feeders such as oysters. Methods of making the liposoils is also disclosed.

Abstract translation: 公开了一类新型脂质囊泡，脂油脂，含油量高，含水量低，蛋白质含量高。 脂肪油是使用表面活性剂和干燥的蛋黄或干燥的全蛋作为壁材料，油和水性稀释剂的组合制成的。 与大多数脂质囊泡不同，脂质体可以用具有高盐度的水性稀释剂制成; 事实上，海水是优选的水性稀释剂。 脂质体作为海洋环境的食物具有特别的适用性，例如过滤饲料如牡蛎的食物来源。 还公开了制备脂质体的方法。

公开(公告)号：US5547677A

公开(公告)日：1996-08-20

申请号：US246868

申请日：1994-05-20

Applicant: D. Craig Wright

Inventor： D. Craig Wright

IPC: A61K9/127 ,  A61K31/14 ,  A61K31/23 ,  A61K45/06 ,  A61K7/40 ,  A61K9/107

CPC classification number: A61K45/06 ,  A61K31/14 ,  A61K31/23 ,  A61K9/1272

Abstract: An antimicrobial lipid-containing oil-in-water emulsion comprising an agent selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate as the primary lipid and a cationic halogen-containing compound having a C.sub.12 -C.sub.16 chain as a positive charge producing agent is disclosed. The antimicrobial emulsion can be used in the form of a pharmaceutical preparation to inhibit the growth of a wide variety of infectious pathogens.